Stockscreener 앱 받기
1.465
5.40%
0.075
Editas Medicine Inc 주식(EDIT)의 최신 뉴스
Editas Medicine (EDIT) to Release Quarterly Earnings on Wednesday - MarketBeat
Zacks Research Comments on Editas Medicine FY2027 Earnings - MarketBeat
Genome Editing Market Future Business Opportunities 2025-2032 - openPR.com
Susquehanna Fundamental Investments LLC Acquires New Stake in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright Estimates Editas Medicine Q1 Earnings - MarketBeat
Cantor Fitzgerald Upgrades Editas Medicine (NASDAQ:EDIT) to "Strong-Buy" - MarketBeat
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May - GlobeNewswire
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor ... - Bluefield Daily Telegraph
Editas Medicine Earnings Alert: Q1 2025 Results Coming May 12, Ends Quarterly Calls - Stock Titan
Editas Medicine (NASDAQ:EDIT) Stock Rating Upgraded by HC Wainwright - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Receives $6.83 Consensus Target Price from Analysts - MarketBeat
Editas Medicine Inc expected to post a loss of 58 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Purchases New Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
HC Wainwright & Co. Initiates Coverage of Editas Medicine (LSE:0IFK) with Buy Recommendation - Nasdaq
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Barchart.com
Editas Medicine (EDIT) Receives Positive Coverage from H.C. Wain - GuruFocus
HC Wainwright & Co. Initiates Coverage of Editas Medicine (EDIT) with Buy Recommendation - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting | EDIT Stock N - GuruFocus
Editas Medicine to Present Five Abstracts at the 28th Annual Meeting of the American Society of Gene and Cell Therapy - Nasdaq
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - The Manila Times
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in ... - Bluefield Daily Telegraph
Editas Unveils Game-Changing In Vivo Gene Editing Breakthroughs: 5 Major Studies at ASGCT 2025 - Stock Titan
Recent uptick might appease Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners after losing 71% over the past year - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Leerink Partnrs Forecasts Editas Medicine Q3 Earnings - MarketBeat
Cell and Gene Therapy Market Investment Trends & Emerging - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) institutional owners may be pleased with recent gains after 71% loss over the past year - Yahoo Finance
Leerink Partnrs Weighs in on Editas Medicine Q1 Earnings - MarketBeat
New Horizons in Biomedical CRISPR Gene Editing Market Exploring - openPR.com
Leber Congenital Amaurosis Market to Show Remarkable Growth - openPR.com
Raymond James Financial Inc. Takes $303,000 Position in Editas Medicine, Inc. (NASDAQ:EDIT) - MarketBeat
Genome Editing Market Growth 2025: Trends, Consumer Demand, - openPR.com
SEC Form PRE 14A filed by Editas Medicine Inc. - Quantisnow
Why Is Editas (EDIT) Down 37.1% Since Last Earnings Report? - Yahoo Finance
Editas Medicine: Do The Risks Outweigh The Rewards? (NASDAQ:EDIT) - Seeking Alpha
Top 5 CRISPR Companies To Invest In (May 2025) - Securities.io
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates - MSN
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline - Investing.com
Editas Medicine stock hits 52-week low at $1.12 amid sharp decline By Investing.com - Investing.com South Africa
RNA Pioneer and Former Editas CEO Joins Codexis Board: Strategic Move for RNA Therapeutics Push - Stock Titan
5.73%
1.07%
자본화:
|
볼륨(24시간):